PL427987A1 - Method for modifying arsenic concentration - Google Patents

Method for modifying arsenic concentration

Info

Publication number
PL427987A1
PL427987A1 PL427987A PL42798718A PL427987A1 PL 427987 A1 PL427987 A1 PL 427987A1 PL 427987 A PL427987 A PL 427987A PL 42798718 A PL42798718 A PL 42798718A PL 427987 A1 PL427987 A1 PL 427987A1
Authority
PL
Poland
Prior art keywords
modifying
arsenic
arsenic concentration
average
level
Prior art date
Application number
PL427987A
Other languages
Polish (pl)
Inventor
Jan LUBIŃSKI
Wojciech MARCINIAK
Róża Derkacz
Piotr Baszuk
Original Assignee
Pomorski Uniwersytet Medyczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomorski Uniwersytet Medyczny W Szczecinie filed Critical Pomorski Uniwersytet Medyczny W Szczecinie
Priority to PL427987A priority Critical patent/PL427987A1/en
Publication of PL427987A1 publication Critical patent/PL427987A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Zgłoszenie opisuje sposób podwyższania poziomu arsenu we krwi. Sposób ten charakteryzuje się tym, że zwiększenie poziomu arsenu w pożywieniu średnio o 1,5 mg As na tydzień skutkuje wzrostem poziomu arsenu we krwi z wartości wyjściowej 0,54 µg/l (±0,18 µg/l) średnio o 0,20 ug/l (±0,25) po 2 tygodniach oraz średnio o 0,60 µg/l (±0,41) po 3 miesiącach.The application describes a method of increasing the level of arsenic in the blood. This method is characterized by the fact that increasing the level of arsenic in the food by an average of 1.5 mg As per week results in an increase in the level of arsenic in the blood from the starting value of 0.54 µg / l (± 0.18 µg / l) by an average of 0.20 µg / l (± 0.25) after 2 weeks and on average 0.60 µg / l (± 0.41) after 3 months.

PL427987A 2018-11-30 2018-11-30 Method for modifying arsenic concentration PL427987A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL427987A PL427987A1 (en) 2018-11-30 2018-11-30 Method for modifying arsenic concentration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL427987A PL427987A1 (en) 2018-11-30 2018-11-30 Method for modifying arsenic concentration

Publications (1)

Publication Number Publication Date
PL427987A1 true PL427987A1 (en) 2020-06-01

Family

ID=70855721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL427987A PL427987A1 (en) 2018-11-30 2018-11-30 Method for modifying arsenic concentration

Country Status (1)

Country Link
PL (1) PL427987A1 (en)

Similar Documents

Publication Publication Date Title
PH12020500601A1 (en) Contraceptive composition with reduced cardiovascular effects
EA201792273A1 (en) COMPOSITIONS CONTAINING A COMBINATION OF ANTI-PD-1 ANTIBODIES AND OTHER ANTIBODIES
MX2018015069A (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid.
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
MX2021011297A (en) Oral care compositions for active agent delivery.
EA201890767A1 (en) C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS
NZ732241A (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
EA201890811A1 (en) METHODS OF TREATMENT OF MUSCULAR DISTROPHIA
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
PH12019502886A1 (en) Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
MX2020010968A (en) Buffered formulations of bevacizumab for use of treating diseases.
WO2017079443A8 (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
MX2020012979A (en) Methods for increasing sepiapterin plasma exposure.
EA202091095A1 (en) ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGUES
AR117407A1 (en) STABLE AQUEOUS FORMULATIONS OF ANTI-TAU ANTIBODIES
MX2023011670A (en) Stable anti-osmr antibody formulation.
WO2015134627A4 (en) Methods for treating cancer with notch1 antibodies
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
PH12019502277A1 (en) Crystalline forms of (s)-afoxolaner
MX2020009496A (en) Method for treating asthma or allergic disease.
PL427987A1 (en) Method for modifying arsenic concentration
EA201892842A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID
EA201891752A3 (en) PHARMACEUTICAL COMPOSITION TO IMPROVE CONDITION DURING CHRONIC RENAL INSUFFICIENCY OR TO PREVENT ITS PROGRESSION
MA54511B1 (en) Nutraceutical ophthalmic composition for the treatment of retinal pathologies with a neovascular component
MX2019002142A (en) Superfood supplement for dogs and its manufacturing process.